ANDA 202802, held by Actavis Elizabeth. Lisdexamfetamine Dimesylate.
As of Nov 16, 2026, ANDA 202802 (Lisdexamfetamine Dimesylate), held by Actavis Elizabeth, was first approved by FDA on Aug 25, 2023, with 1 approved supplement and 0 published complete response letters.
Lisdexamfetamine dimesylate capsules are indicated for the treatment of: Attention Deficit Hyperactivity Disorder (ADHD) in adults and pediatric patients 6 years and older. Moderate to severe binge eating disorder (BED) in adults. Limitations of Use: The use of lisdexamfetamine dimesylate capsules is not recommended in pediatric patients younger than 6 years of age because they had higher plasma exposure and a higher incidence of adverse reactions (e.g., weight loss) than patients 6 years and older at the same dosage. Lisdexamfetamine dimesylate capsules are not indicated or recommended for weight loss.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Aug 25, 2023 | Original application | Approved |
| Lisdexamfetamine Dimesylate10MG · capsule;oral | Lisdexamfetamine Dimesylate | Rx |
| Lisdexamfetamine Dimesylate20MG · capsule;oral | Lisdexamfetamine Dimesylate | Rx |
| Lisdexamfetamine Dimesylate30MG · capsule;oral | Lisdexamfetamine Dimesylate | Rx |
| Lisdexamfetamine Dimesylate40MG · capsule;oral | Lisdexamfetamine Dimesylate | Rx |
| Lisdexamfetamine Dimesylate50MG · capsule;oral | Lisdexamfetamine Dimesylate | Rx |
| Lisdexamfetamine Dimesylate60MG · capsule;oral | Lisdexamfetamine Dimesylate | Rx |
| Lisdexamfetamine Dimesylate70MG · capsule;oral | Lisdexamfetamine Dimesylate | Rx |
| Sep 16, 2024 | Supplement 2Labeling · Standard review | Approved | None posted |
| Aug 25, 2023 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters